Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sulfonamide compound in chronic airway inflammatory diseases

A technology of chronic inflammation and general formula compounds, which is applied in the medical field and can solve the problems of not being able to apply to all types of diseases and unsatisfactory effects

Active Publication Date: 2015-11-04
ZHEJIANG UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the above method cannot be applied to all types of diseases, and the effect is not ideal.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sulfonamide compound in chronic airway inflammatory diseases
  • Application of sulfonamide compound in chronic airway inflammatory diseases
  • Application of sulfonamide compound in chronic airway inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0139] Example 1 Effect of Compound A on eosinophil infiltration-based airway inflammation:

[0140] method:

[0141] 1) Choose 8-week-old healthy mice;

[0142] 2) Sensitization: mice were intraperitoneally injected with sensitization solution on days 0 and 14;

[0143] 3) Allergen atomization challenge: on the 24th, 25th, and 26th day, put the mice in a closed container, and inhale the allergen solution for 40 minutes, for three consecutive days.

[0144] 4) The control group was sensitized and aerosolized with the same dose of normal saline instead of allergens.

[0145] 5) Compound A airway topical drug treatment:

[0146] Ⅰ) Administration time: 4 hours after the allergen aerosol challenge on the 24th, 25th, and 26th day, for three consecutive days;

[0147] Ⅱ) Dosage: Compound A100ug / mouse;

[0148] Ⅲ) Administration method: airway administration in mice under anesthesia;

[0149] Ⅳ) The control group was administered with the same dose of Compound A solvent airway...

Embodiment 2

[0154] Example 2 Effect of Compound A on neutrophil infiltration-based airway inflammation:

[0155] method:

[0156] 1) Choose 8-week-old healthy mice;

[0157] 2) Sensitization: mice were intraperitoneally injected with sensitization solution on day 0;

[0158] 3) Allergen atomization challenge: on the 14th day, put the mice in a closed container, and inhale the allergen solution by atomization for 40 minutes.

[0159] 4) The control group was sensitized and aerosolized with the same dose of normal saline instead of allergens.

[0160] 5) Compound A airway topical drug treatment:

[0161] Ⅰ) Administration time: 4 hours after allergen aerosol challenge on the 14th day;

[0162] Ⅱ) Dosage: Compound A100ug / mouse;

[0163] Ⅲ) Administration method: airway administration in mice under anesthesia;

[0164] Ⅳ) The control group was administered with the same dose of Compound A solvent airway.

[0165] result:

[0166] (1) Airway administration of Compound A inhibited the r...

Embodiment 3

[0168] The dose selection of embodiment 3Compound A

[0169] 1) Choose 8-week-old healthy mice;

[0170] 2) Sensitization: mice were intraperitoneally injected with sensitization solution on day 0;

[0171] 3) Allergen atomization challenge: on the 14th day, put the mice in a closed container, and inhale the allergen solution by atomization for 40 minutes.

[0172] 4) The control group was sensitized and aerosolized with the same dose of normal saline instead of allergens.

[0173] 5) Compound A airway topical drug treatment:

[0174] Ⅰ) Administration time: 4 hours after allergen aerosol challenge on the 14th day;

[0175] Ⅱ) Dosage: Group A: Compound A50ug / mouse, Group B: Compound A100ug / mouse; Group C: Compound A250ug / mouse; Group D: Compound A500ug / mouse; Group E: Compound A1000ug / mouse.

[0176] Ⅲ) Administration method: airway administration in mice under anesthesia;

[0177] Ⅳ) The control group was administered with the same dose of Compound A solvent airway.

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

Provided is an application of a sulfonamides compound (i.e. the compound represented by general formula I) in chronic airway inflammatory diseases, particularly the use of Compound A or analogues thereof (Compound A1), for preparing a pharmaceutical composition treating diseases related to chronic airway inflammation. Compound A or analogues thereof of the present invention can reduce invasion and recruitment of inflammatory cells, particularly neutrophil granulocyte, and induce apoptosis of inflammatory cells, thus being used for chronic airway diseases such as bronchial asthma and COPD, and particularly for the treatment of chronic airway diseases where glucocorticoid has no effect.

Description

technical field [0001] The present invention belongs to the field of medical treatment, and specifically relates to the application of sulfonamide compounds, that is, compounds of the general formula shown in formula I (such as compound A, A1) in the treatment of airway chronic inflammatory diseases. Background technique [0002] Chronic airway inflammatory diseases such as bronchial asthma and chronic obstructive pulmonary disease are non-specific inflammatory diseases involving the participation of airway intrinsic cells, inflammatory cells and inflammatory factors under the action of various internal and external stimuli. As far as asthma is concerned, it is participated by inflammatory cells (such as eosinophils, mast cells, basophils, T lymphocytes, neutrophils, smooth muscle cells, airway epithelial cells, etc.) and cellular components, mainly The characteristics include chronic inflammation of the airway, extensive and variable reversible airflow limitation, hyperresp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/635A61P29/00A61P11/00A61P11/06
CPCA61K31/145A61K31/495A61K31/63
Inventor 沈华浩应颂敏田宝平陈志华李雯
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com